Molecular Partners Reports Positive First-in-Human Imaging Data for DLL3-Targeting Radiotherapy MP0712

summarizeResume

This 6-K filing provides the first clinical data for MP0712, a DLL3-targeted radiotherapy, following the initiation of its Phase 1/2a study. The reported imaging and dosimetry data from five patients demonstrated specific tumor uptake and a clean profile in healthy organs, which is a critical early indicator of a drug's potential safety and efficacy. These positive results validate the company's Radio-DARPin platform and significantly de-risk the early clinical development of MP0712, reinforcing its potential for treating small cell lung cancer and other neuroendocrine malignancies. Investors will be watching for further data from the ongoing Phase 1/2a study later in 2026.

check_boxEvenements cles

• Positive First-in-Human Data

  Initial imaging and dosimetry data for MP0712 showed specific tumor accumulation and favorable biodistribution in five patients with DLL3-expressing cancers, indicating therapeutic potential.

• Supports Clinical Development

  The data validates assumptions and supports the ongoing Phase 1/2a study of MP0712 with the therapeutic isotope 212Pb, with initial clinical data expected in 2026.

• Conference Call Scheduled

  Molecular Partners will host a webcast on February 2, 2026, to discuss the new clinical data with a nuclear medicine expert.

auto_awesomeAnalyse

This 6-K filing provides the first clinical data for MP0712, a DLL3-targeted radiotherapy, following the initiation of its Phase 1/2a study. The reported imaging and dosimetry data from five patients demonstrated specific tumor uptake and a clean profile in healthy organs, which is a critical early indicator of a drug's potential safety and efficacy. These positive results validate the company's Radio-DARPin platform and significantly de-risk the early clinical development of MP0712, reinforcing its potential for treating small cell lung cancer and other neuroendocrine malignancies. Investors will be watching for further data from the ongoing Phase 1/2a study later in 2026.